Accordingly, the National Comprehensive Cancer Network (NCCN) NSCLC guidelines had recommended the routine detection of EGFR or ERBB2 mutations, or ALK, ROS1, or RET fusions prior to treatment. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.